Bio-Techne/$TECH
1D1W1MYTD1Y5YMAX
Capital at risk
About Bio-Techne
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
- Ticker
- $TECH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,000
- Headquarters
- Minneapolis, United States
- Website
- www.bio-techne.com
Bio-Techne Metrics
BasicAdvanced
$11B
62.34
$1.16
1.28
$0.32
0.44%
Price and volume
Market cap
$11B
Beta
1.28
52-week high
$72.62
52-week low
$43.20
Average daily volume
3M
Dividend rate
$0.32
Financial strength
Current ratio
4.547
Quick ratio
2.94
Long term debt to equity
13.004
Total debt to equity
13.712
Dividend payout ratio (TTM)
27.45%
Interest coverage (TTM)
28.51%
Profitability
EBITDA (TTM)
355.054
Gross margin (TTM)
66.24%
Net profit margin (TTM)
14.97%
Operating margin (TTM)
21.21%
Effective tax rate (TTM)
24.44%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
6.67%
Return on equity (TTM)
9.03%
Valuation
Price to earnings (TTM)
62.336
Price to revenue (TTM)
9.282
Price to book
5.35
Price to tangible book (TTM)
13.61
Price to free cash flow (TTM)
42.845
Free cash flow yield (TTM)
2.33%
Free cash flow per share (TTM)
1.688
Dividend yield (TTM)
0.44%
Forward dividend yield
0.44%
Growth
Revenue change (TTM)
-0.38%
Earnings per share change (TTM)
152.17%
3-year revenue growth (CAGR)
2.25%
10-year revenue growth (CAGR)
9.31%
3-year earnings per share growth (CAGR)
-12.97%
10-year earnings per share growth (CAGR)
5.18%
What the Analysts think about Bio-Techne
Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.
Analyst projections of the future price of Bio-Techne stock.
Bulls say / Bears say
Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash—an enterprise value of $11.3 billion representing a 36% premium over its one-month VWAP—underscoring validation of its strategic assets (Reuters)
In Q4 FY2026, organic revenue grew 3% year-over-year to $321.2 million, exceeding Street expectations and demonstrating resilient end-market demand (Reuters)
Growth across its research and diagnostics businesses drove the Q4 beat, highlighting the benefits of its diversified portfolio beyond protein sciences (Reuters)
Q3 revenue of $311.4 million fell short of the $317.1 million consensus, triggering a 12.8% share drop and highlighting exposure to funding cycles (Reuters)
Sales in its largest protein sciences unit declined 1% to $226.2 million in Q3, signaling softness in its core segment and potential market saturation (Reuters)
Q3 revenues dipped 2% due to order timing issues and lagging spending by emerging biotech customers, underscoring cyclical demand volatility (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Bio-Techne Financial Performance
Revenues and expenses
Bio-Techne Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bio-Techne News
AllArticlesVideos
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
Business Wire3 weeks ago
Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Reuters4 weeks ago
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH
Business Wire2 months ago
Funds containing Bio-Techne
AllUSDEURGBP
Fund name | Fund size | $TECH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.27% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.27% |
iShares Healthcare Innovation£DRDR | £1B | 1.27% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.26% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.26% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.